Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hector Rubio-Zapata"'
Autor:
Felix-Julian Campos-Garcia, Addy-Manuela Castillo-Espinola, Carolina-Elizabeth Medina-Escobedo, Juan C. Zenteno, Julio-Cesar Lara-Riegos, Hector Rubio-Zapata, David Cruz-Robles, Ana-Isabel Velazquez-Ibarra
Publikováno v:
Cardiogenetics, Vol 12, Iss 3, Pp 253-260 (2022)
22q11.2 deletion syndrome is a phenotypic spectrum that encompasses DiGeorge syndrome (OMIM: 188400) and velocardiofacial syndrome (OMIM: 192430). It is caused by a 1.5–3.0 Mb hemizygous deletion of locus 22q11.2, which leads to characteristic faci
Externí odkaz:
https://doaj.org/article/ff491e9df9124a979c3d5ee514910554
Autor:
Víctor Yáñez-Pérez, Amanda Sánchez-Recillas, Salvador Flores-Guido, Maximiliano Ibarra-Barajas, Hector Rubio-Zapata, Rolffy Ortiz-Andrade, Gabriela Ávila-Villarreal
Publikováno v:
European Journal of Medicinal Plants. 24:1-11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf0d5255f441c0ce1d73b10725e10f9a
https://doi.org/10.9734/ejmp/2018/42504
https://doi.org/10.9734/ejmp/2018/42504
Autor:
Maria E. Widman-Valencia, Luis F. Gongora-Meza, Héctor Rubio-Zapata, Rita E. Zapata-Vázquez, Elma Vega Lizama, Marco Ramírez Salomón, Damaris Estrella-Castillo
Publikováno v:
Behavioural Neurology, Vol 2021 (2021)
This study is aimed at identifying the relationship between oral motor treatment and the improvement of abilities for feeding and swallowing in boys and girls with CP residing in the state of Yucatán. The sample consisted of 30 patients with a diagn
Externí odkaz:
https://doaj.org/article/4c35b81883bf4aad8429b604266f2d0b
Autor:
Carla Georgina Cicero-Sarmiento, Rolffy Ortiz-Andrade, Jesús Alfredo Araujo-León, Maira Rubí Segura-Campos, Priscila Vazquez-Garcia, Héctor Rubio-Zapata, Efrén Hernández-Baltazar, Victor Yañez-Pérez, Amanda Sánchez-Recillas, Juan Carlos Sánchez-Salgado, Emanuel Hernández-Núñez, Durcy Ruiz-Ciau
Publikováno v:
Scientia Pharmaceutica, Vol 90, Iss 2, p 28 (2022)
We developed a naringenin–hesperidin molar mixture (MIX–160) with proven antihyperglycemic and vasorelaxant activity in preclinical studies. A solid dosage form was manufactured to improve the bioavailability properties. In the current study, we
Externí odkaz:
https://doaj.org/article/0b1bb7fd05b346018657432485829103